https://www.selleckchem.com/products/ca-170.html
To identify potential biomarkers of preclinical and clinical progression in chromosome 9 open reading frame 72 gene ( -associated disease by assessing the expression levels of plasma microRNAs (miRNAs) in patients and presymptomatic carriers. The PREV-DEMALS study is a prospective study including 22 patients, 45 presymptomatic mutation carriers and 43 controls. We assessed the expression levels of 2576 miRNAs, among which 589 were above noise level, in plasma samples of all participants using RNA sequencing. The expression levels of the
Gefällt mir
Kommentar
Teilen
